Kymera Therapeutics shared clinical data demonstrating dose-dependent knockdown and no dose-limiting toxicities from its ongoing Phase I dose escalation clinical trials for its small molecule protein degrader medicines, KT-333 and KT-413.

The company announced data from its multicentre, open-label, dose-escalation Phase I study (NCT05225584) for KT-333, which evaluates its safety and efficacy in relapsed or refractory lymphomas, large granular lymphocytic leukaemia, and solid tumours.

Safety and efficacy data from multicentre, open-label, dose-escalation Phase I trial (NCT05233033) of KT-413 in relapsed and/or refractory B-cell non-Hodgkin’s lymphomas (NHL) was also reported.

According to GlobalData, there are more than 700 immuno-oncology products currently in Phases I–III of development in the eight major pharmaceutical markets, including the US and China. Approximately 34% of these pipeline drugs are being evaluated for solid tumours.

GlobalData is the parent company of Clinical Trials Arena.

KT-333 is a degrader of signal transducer and activator of transcription 3 (STAT3), a transcriptional regulator that has been linked to various cancers, and inflammatory and autoimmune diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

KT-413 is a heterobifunctional degrader targeting both interleukin-1 receptor-associated kinase 4 (IRAK4) and the immunomodulatory drug (IMiD) substrates, Ikaros and Aiolos.

Clinical trial data for KT-333 will be presented at the International Conference on Malignant Lymphoma (ICML) taking place between 13 and 17 June in Lugano, Switzerland.

KT-333 clinical data

As of the data cut-off of 1 May, 13 patients received a mean of five doses across the first four dose levels. Kymera reported dose-dependent plasma exposure and STAT3 degradation with a mean maximum reduction of up to 88% in peripheral blood mononuclear cells.

No dose-limiting toxicities (DLTs) have been observed in the study.

KY-413 NHL data

As of the data cut-off of 1 June, five patients have received the first four dose levels of KY-413. Kymera reported dose-dependent plasma exposure and targeted degradation of up to 70% IRAK4 was observed after a single dose.

As of the data cut-off, no DLTs or drug-related neutropenia were observed.